VOZRIA
Live / Registered — Registered (as of 09 Nov 2021)
What this means for you
Registered since 09 Nov 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79306175
- Registration number
- 6549771
- Mark type
- Stylized text
- Filed
- 08 Jan 2021
- Published for opposition
- 24 Aug 2021
- Registered
- 09 Nov 2021
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, immunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disorders, namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), hpv, rsv, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders, namely, disorders of the endocrine system, namely, growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders, namely, arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment, namely, nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disorders, namely, thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries, namely, connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, sports injuries, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders, namely, dermatitis, skin and skin structure infections, namely, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disorders, namely, hypogonadism, testosterone/androgen disorders and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders, namely, irritable bowel disorders and symptoms, digestive disorders and acid-related disorders; pharmaceutical preparations for the treatment of sexual dysfunction, namely, erectile dysfunction, male and female sexual dysfunction disorders, namely, arousal disorder, pain disorder, desire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases and disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders, namely, amenorrhoea, dysmenorrheal and infertility; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor/menopausal symptoms, endometriosis/uterine fibroids, leiomyoma, endourology/stone, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders, namely, polycystic ovary syndrome; pharmaceutical preparations for the treatment of hepatological related diseases, namely, hepatitis, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of damaged skin and tissue, namely, bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines
Owner
Prosecution history
- 30 May 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 30 Jul 2023 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 12 Mar 2022 — NOTIFICATION PROCESSED BY IB
- 23 Feb 2022 — FINAL DISPOSITION NOTICE SENT TO IB
- 22 Feb 2022 — FINAL DISPOSITION PROCESSED
- 09 Dec 2021 — GRANT OF PROTECTION CREATED, TO BE SENT TO IB
- 09 Nov 2021 — REGISTERED-PRINCIPAL REGISTER
- 24 Aug 2021 — PUBLISHED FOR OPPOSITION
- 22 Aug 2021 — NOTIFICATION PROCESSED BY IB
- 04 Aug 2021 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 04 Aug 2021 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 04 Aug 2021 — NOTICE OF PUBLICATION
- 20 Jul 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 19 Jul 2021 — ASSIGNED TO EXAMINER
- 19 Mar 2021 — APPLICATION FILING RECEIPT MAILED